- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Profit falls at Lilly but meets Wall Street expectations
October 20, 2011
J.K. WallThe Indianapolis-based drugmaker earned $1.24 billion in the three months ended Sept. 30, down 5 percent from the same quarter
a year ago, even as revenue surged 9 percent.
MoreLilly diabetes drug wins approval for expanded use
October 19, 2011
Bloomberg NewsEli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s
top-selling insulin to treat Type 2 diabetes.
MoreLilly announces replacements for two retiring executives
October 11, 2011
J.K. WallBryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing
operations, both will retire on Dec. 31.
MoreLilly gets dinged for job cuts
October 10, 2011
J.K. WallEli Lilly and Co. got called out in a recent report on companies that took advantage of the 2004 tax holiday on foreign profits
and have since slashed jobs.
MoreLilly slashes water use, reduces waste output
October 8, 2011
IBJ StaffBy 2013, Lilly hopes to reduce water intake another 5 percent, while reducing the amount of waste sent to landfills an additional
20 percent.
MoreFDA approves Cialis for enlarged prostate
October 7, 2011
Cialis, Lilly's blockbuster erectile dysfunction drug, now can be taken to treat enlarged prostate. FDA approval means men
who suffer from both disorders can take one medication.
MoreLilly CEO says he's not interested in Pfizer animal unit
October 5, 2011
Bloomberg NewsDrugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter
said Wednesday.
MoreEli Lilly, Turkish firm in talks to sell drugs in 26 nations
October 3, 2011
Bloomberg NewsEli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to
sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
MoreLilly's Alimta get favorable opinion for new use in Europe
September 26, 2011
J.K. WallIf approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients,
generating more revenue.
MoreDebate rages over whether Lilly's Byetta lifts cancer risk
September 16, 2011
Bloomberg NewsA German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
MoreFDA gets new report on Lilly diabetes drug
September 12, 2011
Associated PressDrugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly
diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
MoreFDA deal with drugmakers raises user fees 6 percent
September 1, 2011
Bloomberg NewsDrugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing
the drug-approval process through fiscal 2017.
MoreLilly spent $1.9M lobbying feds in first quarter
August 21, 2011
Associated PressEli Lilly and Co. spent $1.9 million lobbying the federal government in the first quarter, focusing on the health care overhaul
and overseas pricing reform, among many other issues.
MoreEli Lilly's Elanco unit blossoming at just the right time
July 30, 2011
Greg AndrewsAn investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass
$3 billion by 2018.
MoreLilly wins appeals court ruling in Strattera patent case
July 29, 2011
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s
patent on attention-deficit treatment Strattera was invalid.
MoreDespite sales spike, Effient has middling prospects
July 25, 2011
J.K. WallRemember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow
launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
MoreLilly stock rises after drugmaker reports higher sales
July 21, 2011
Investors responded favorably Thursday to Eli Lilly and Co.’s surprisingly strong second-quarter revenue, even though
its profit fell due to rapid spending on marketing and research.
MorePfizer won’t break up animal unit for potential Lilly bid
July 21, 2011
Bloomberg NewsPfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after
Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
MoreLilly profit falls, but forecast rises after second quarter
July 21, 2011
J.K. WallSecond-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts
by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
MoreLilly: Alzheimer's patients on failed drug didn’t improve
July 19, 2011
Bloomberg NewsEli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug
semagacestat didn’t improve after dosing was halted.
MoreFDA says potential diabetes drug may cause cancer
July 18, 2011
Bloomberg NewsDapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients
excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar
drugs.
MoreLilly's Cialis finally overtakes Viagra
July 11, 2011
J.K. WallWhy do drugmakers still pursue so many me-too drugs? Because, if marketed well, they can be extremely lucrative. Just ask
Eli Lilly and Co. about its drug Cialis.
MoreLechleiter: German drug pricing creates 'uncertainty' for Lilly
July 11, 2011
Bloomberg NewsEli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy
creates “uncertainty” for the company’s business planning.
MoreEli Lilly using big dividend to prevent investor exodus
July 9, 2011
Greg AndrewsLilly executives are emphatic that they have no plans to reduce the company's 49-cents-a-share quarterly cash dividend,
which gives the stock a rich annual yield of 5.2 percent.
MoreJ&J completes sale of animal-drug business to Lilly
July 7, 2011
Associated PressJanssen Pharmaceutica said Thursday it has completed the sale of its animal health business to Eli Lilly and Co. Inc.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Laura-the festivals and tastings are free. What does is strengthen the sense of community with activities. What are those empty lots doing for the Village? it's sad you can't see the good that this progress can do for the area. No one is requiring anyone to shop there. I guess you'd rather see a Dollar store move in or no, we'd rather see the property stand empty b/c change is out of the question.
Read down to the part about Brizzi. Someone needs to subpoena his "purchases" of Red RockPictures and Cellstar and his corresponding bank records, I mean c'mon, I'd like to see his alcohol usage records, too. http://diana-vice.blogspot.com/2011_01_01_archive.html
Wonder if my neighborhood can advertise our "retention" pond and act like it is a beach too?
a new record at the '11 salebration until they realized that it was a futile effort to get their crapwagon moter and crapwagon car up speed. And then they just quietly slunk off into the night and never spoke of it again. Nothing to see here folks.
millions for putting a company's bumper sticker on one of its Lolas. But you gotta take what you can get.